Volume 1, Issue 5, Pages (May 2005)

Slides:



Advertisements
Similar presentations
Volume 14, Issue 2, Pages (August 2011)
Advertisements

Volume 14, Issue 6, Pages (December 2011)
Volume 20, Issue 1, Pages (July 2014)
Lymphatics as a New Active Player in Reverse Cholesterol Transport
Volume 2, Issue 4, Pages (October 2005)
Volume 14, Issue 4, Pages (October 2011)
Volume 16, Issue 1, Pages (July 2012)
Wip1-Dependent Regulation of Autophagy, Obesity, and Atherosclerosis
Volume 23, Issue 3, Pages (March 2016)
Volume 15, Issue 1, Pages (January 2012)
Volume 15, Issue 5, Pages (May 2012)
Volume 15, Issue 4, Pages (April 2012)
Volume 22, Issue 8, Pages (February 2018)
Volume 8, Issue 4, Pages (October 2008)
Volume 102, Issue 6, Pages (September 2000)
Ling Yang, Ping Li, Suneng Fu, Ediz S. Calay, Gökhan S. Hotamisligil 
Volume 17, Issue 4, Pages (April 2013)
Volume 20, Issue 5, Pages (November 2014)
Volume 24, Issue 2, Pages (August 2016)
Volume 120, Issue 2, Pages (January 2005)
Volume 15, Issue 3, Pages (March 2012)
Molecular Therapy - Nucleic Acids
Volume 15, Issue 2, Pages (February 2012)
Volume 12, Issue 4, Pages (October 2010)
Volume 14, Issue 6, Pages (December 2011)
New Therapeutic Approaches to the Treatment of Dyslipidemia
Guido T. Bommer, Ormond A. MacDougald  Cell Metabolism 
Volume 17, Issue 5, Pages (May 2013)
Volume 7, Issue 3, Pages (March 2008)
Volume 12, Issue 2, Pages (August 2010)
Autophagy Links Inflammasomes to Atherosclerotic Progression
Molecular Therapy - Nucleic Acids
Volume 12, Issue 3, Pages (September 2010)
Volume 13, Issue 8, Pages (November 2015)
Volume 8, Issue 6, Pages (December 2008)
Volume 18, Issue 1, Pages (July 2013)
Volume 7, Issue 2, Pages (February 2008)
Volume 2, Issue 3, Pages (September 2000)
Volume 93, Issue 5, Pages (May 1998)
Volume 1, Issue 2, Pages (February 2005)
Heat Shock Transcription Factor 1 Is a Key Determinant of HCC Development by Regulating Hepatic Steatosis and Metabolic Syndrome  Xiongjie Jin, Demetrius.
Volume 9, Issue 5, Pages (May 2009)
Volume 136, Issue 6, Pages (March 2009)
Volume 3, Issue 4, Pages (April 2006)
Volume 10, Issue 1, Pages (July 2009)
Volume 10, Issue 5, Pages (November 2009)
Volume 19, Issue 2, Pages (February 2014)
Volume 14, Issue 1, Pages (July 2011)
Volume 5, Issue 6, Pages (June 2007)
Volume 16, Issue 4, Pages (October 2012)
Volume 15, Issue 3, Pages (March 2012)
Volume 18, Issue 1, Pages (July 2013)
Volume 8, Issue 6, Pages (December 2008)
Volume 14, Issue 4, Pages (October 2011)
Volume 18, Issue 2, Pages (August 2013)
Volume 3, Issue 2, Pages (February 2006)
Volume 6, Issue 3, Pages (September 2007)
Volume 9, Issue 5, Pages (May 2009)
Volume 4, Issue 5, Pages (November 2006)
Volume 21, Issue 2, Pages (February 2015)
Induction of Leptin Resistance by Activation of cAMP-Epac Signaling
Volume 14, Issue 2, Pages (August 2011)
Volume 23, Issue 1, Pages (January 2016)
Aishwarya Sathyanarayan, Mara T. Mashek, Douglas G. Mashek 
Volume 27, Issue 4, Pages e4 (April 2018)
Volume 1, Issue 3, Pages (March 2005)
Volume 140, Issue 3, Pages (March 2011)
Hepatic Proprotein Convertases Modulate HDL Metabolism
Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice  Jun Yoshino, Kathryn F. Mills,
The GCN2 eIF2α Kinase Regulates Fatty-Acid Homeostasis in the Liver during Deprivation of an Essential Amino Acid  Feifan Guo, Douglas R. Cavener  Cell.
Presentation transcript:

Volume 1, Issue 5, Pages 297-308 (May 2005) Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRα  Michael Lehrke, Corinna Lebherz, Segan C. Millington, Hong-Ping Guan, John Millar, Daniel J. Rader, James M. Wilson, Mitchell A. Lazar  Cell Metabolism  Volume 1, Issue 5, Pages 297-308 (May 2005) DOI: 10.1016/j.cmet.2005.04.005 Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 1 Mice with liver-specific increase in LXRα expression Expression levels of human and mouse LXRα were determined in the liver of AAV-GFP control and AAV-LXRα-treated animals. (A) Analysis of hLXRα gene expression by reverse transcriptase-PCR in liver and macrophages and (B) total LXRα protein levels in liver were measured by Western blot, using HDAC2 as loading control; (C) densitometric quantification of LXR protein levels normalized to HDAC2. *p < 0.05. Results are expressed as the mean ± standard error (SEM). Cell Metabolism 2005 1, 297-308DOI: (10.1016/j.cmet.2005.04.005) Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 2 Increased hepatic LXRα worsens serum lipid profile on a chow diet Serum cholesterol (A) and triglyceride (B) levels in AAV-LXRα and AAV-GFP control LDLR null mice fed on chow diets. Results are mean ± standard error (SEM) of 8–10 animals per group. *p < 0.01. (C) FPLC fractionation of cholesterol. (D) FPLC fractionation of triglycerides. The location of the VLDL, LDL, and HDL fractions are shown. (E) Gene expression in liver of AAV-GFP and AAV-LXRα animals on chow diet measured by Q-PCR. Results are normalized to expression of 36B4, mean expression of GFP group is normalized to 1. Results are expressed as the mean ± standard error (SEM), five animals per group. *p < 0.05. Cell Metabolism 2005 1, 297-308DOI: (10.1016/j.cmet.2005.04.005) Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 3 Hepatic LXRα improves lipid profile on Western diet by increasing the clearance of VLDL Male AAV-LXR and AAV-GFP control LDLR null mice were fed chow diet then switched to Western diet. Serum cholesterol (A) and triglyceride (B) were measured at the indicated times. *p < 0.05, **p < 0.01. (C) FPLC fractionation of cholesterol. (D) FPLC fractionation of triglycerides of pooled serum on Western diet (n = 8–10/group). The location of the VLDL, LDL, and HDL fractions are shown. (E) Triglyceride secretion rate on Western diet (n = 7/group, p < 0.05 at baseline, p = n.s. at other time points). (F) VLDL clearance on Western diet (n = 5/group, control normalized to 1); *p < 0.05. Results are expressed as the mean ± standard error (SEM). Cell Metabolism 2005 1, 297-308DOI: (10.1016/j.cmet.2005.04.005) Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 4 Increased hepatic LXRα alters hepatic gene expression and reduces atherosclerosis on a Western diet A and B) Expression was measured by Q-PCR, with results normalized to expression of 36B4. Mean expression of GFP group is normalized to 1. Results are expressed as the mean ± standard error (SEM) of 8–10 animals per group. *p < 0.05, **p < 0.01, ***p < 0.001. C) Total aortic plaque area (results of individual animals and mean are shown), with representative aortae pictured. D) Atherosclerotic burden at aortic root (results of individual animals and mean are shown), with representative sections shown. n = 12 male mice/group; *p < 0.05, *p < 0.01 versus AAV-GFP. Cell Metabolism 2005 1, 297-308DOI: (10.1016/j.cmet.2005.04.005) Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 5 The synthetic LXR agonist T0901317 reverses the protective effect of hepatic LXRα on lipid profile AAV-GFP and AAV-LXR mice on Western diet were treated with the synthetic LXR agonist T0901317 (T09) (n = 9/group). Serum cholesterol (A) and serum triglycerides (B) are shown prior and post administration. (C) Triglyceride secretion of vehicle- or T09-treated animals on Western diet (n = 5/group, *p < 0.05, **p < 0.01). (D) VLDL clearance of vehicle- or T09-treated animals on Western diet (n = 5/group, control normalized to 1), *p < 0.01. T09 was administered for 3 days. Results are expressed as the mean ± standard error (SEM). Cell Metabolism 2005 1, 297-308DOI: (10.1016/j.cmet.2005.04.005) Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 6 SREBP-1 target genes are induced by synthetic LXR ligand treatment but not by increased LXRα A) Profiling of liver RNA from AAV-GFP ± T09 or AAV-LXRα ± T09 animals on Western diet. The entire dataset is provided in the NCBI/Gene Expression Omnibus database. (A, top) Genes whose mean upregulation was >1.6-fold for AAV-LXRα and/or T09 ligand-treated. Listed in order of fold induction: AAV-GFP/T09 versus AAV-GFP/vehicle. (A, bottom) Genes whose mean upregulation was >1.6-fold by T09 but not by AAV-LXRα in the absence of synthetic ligand. Listed in order of fold induction: AAV-GFP/T09 versus AAV-LXRα/vehicle. B and C) Q-PCR analysis of hepatic gene expression. Results are normalized to expression of β-actin, mean expression of GFP/vehicle group is normalized to 1. n = 4 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001 compared to GFP/vehicle group. No significant differences were found between AAV-GFP/T09 and AAV-LXRα/T09 group. Results are expressed as mean ± standard error (SEM). Cell Metabolism 2005 1, 297-308DOI: (10.1016/j.cmet.2005.04.005) Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 7 Synthetic LXR ligand but not increased hepatic LXRα enhances maturation of SREBP in liver A) Western blot of mature SREBP-1 from liver of vehicle- or T09-treated animals on Western diet; RAN serves as loading control. B) There was no difference in mature SREBP-1 in liver of AAV-GFP- and AAV-LXR-treated animals on Western diet. C) T09 increases maturation of SREBP-1 in AAV-GFP- and AAV-LXR-treated animals. HDAC2 serves as loading control in (B) and (C). D) Summary of the diet- and synthetic ligand-dependent effects of hepatic LXR on lipid metabolism. The major effects of Western diet and synthetic LXR agonist on hepatic LXRα target genes and SREBP-1c maturation are highlighted along with resultant changes in serum lipid chemistries. Cell Metabolism 2005 1, 297-308DOI: (10.1016/j.cmet.2005.04.005) Copyright © 2005 Elsevier Inc. Terms and Conditions